Cargando…
The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial
BACKGROUND: It has been proposed that artemisinin-based combination therapy (ACT) be subsidised in the private sector in order to improve affordability and access. This study in western Kenya aimed to evaluate the impact of providing subsidized artemether–lumefantrine (AL) through retail providers o...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104978/ https://www.ncbi.nlm.nih.gov/pubmed/21655317 http://dx.doi.org/10.1371/journal.pmed.1000437 |
_version_ | 1782204660017266688 |
---|---|
author | Kangwana, Beth P. Kedenge, Sarah V. Noor, Abdisalan M. Alegana, Victor A. Nyandigisi, Andrew J. Pandit, Jayesh Fegan, Greg W. Todd, James E. Brooker, Simon Snow, Robert W. Goodman, Catherine A. |
author_facet | Kangwana, Beth P. Kedenge, Sarah V. Noor, Abdisalan M. Alegana, Victor A. Nyandigisi, Andrew J. Pandit, Jayesh Fegan, Greg W. Todd, James E. Brooker, Simon Snow, Robert W. Goodman, Catherine A. |
author_sort | Kangwana, Beth P. |
collection | PubMed |
description | BACKGROUND: It has been proposed that artemisinin-based combination therapy (ACT) be subsidised in the private sector in order to improve affordability and access. This study in western Kenya aimed to evaluate the impact of providing subsidized artemether–lumefantrine (AL) through retail providers on the coverage of prompt, effective antimalarial treatment for febrile children aged 3–59 months. METHODS AND FINDINGS: We used a cluster-randomized, controlled design with nine control and nine intervention sublocations, equally distributed across three districts in western Kenya. Cross-sectional household surveys were conducted before and after the delivery of the intervention. The intervention comprised provision of subsidized packs of paediatric ACT to retail outlets, training of retail outlet staff, and community awareness activities. The primary outcome was defined as the proportion of children aged 3–59 months reporting fever in the past 2 weeks who started treatment with AL on the same day or following day of fever onset. Data were collected using structured questionnaires and analyzed based on cluster-level summaries, comparing control to intervention arms, while adjusting for other covariates. Data were collected on 2,749 children in the target age group at baseline and 2,662 at follow-up. 29% of children experienced fever within 2 weeks before the interview. At follow-up, the percentage of children receiving AL on the day of fever or the following day had risen by 14.6% points in the control arm (from 5.3% [standard deviation (SD): 3.2%] to 19.9% [SD: 10.0%]) and 40.2% points in the intervention arm (from 4.7% [SD: 3.4%] to 44.9% [SD: 11.7%]). The percentage of children receiving AL was significantly greater in the intervention arm at follow-up, with a difference between the arms of 25.0% points (95% confidence interval [CI]: 14.1%, 35.9%; unadjusted p = 0.0002, adjusted p = 0.0001). No significant differences were observed between arms in the proportion of caregivers who sought treatment for their child's fever by source, or in the child's adherence to AL. CONCLUSIONS: Subsidizing ACT in the retail sector can significantly increase ACT coverage for reported fevers in rural areas. Further research is needed on the impact and cost-effectiveness of such subsidy programmes at a national scale. TRIAL REGISTRATION: Current Controlled Trials ISRCTN59275137 and Kenya Pharmacy and Poisons Board Ethical Committee for Clinical Trials PPB/ECCT/08/07. Please see later in the article for the Editors' Summary |
format | Text |
id | pubmed-3104978 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-31049782011-06-08 The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial Kangwana, Beth P. Kedenge, Sarah V. Noor, Abdisalan M. Alegana, Victor A. Nyandigisi, Andrew J. Pandit, Jayesh Fegan, Greg W. Todd, James E. Brooker, Simon Snow, Robert W. Goodman, Catherine A. PLoS Med Research Article BACKGROUND: It has been proposed that artemisinin-based combination therapy (ACT) be subsidised in the private sector in order to improve affordability and access. This study in western Kenya aimed to evaluate the impact of providing subsidized artemether–lumefantrine (AL) through retail providers on the coverage of prompt, effective antimalarial treatment for febrile children aged 3–59 months. METHODS AND FINDINGS: We used a cluster-randomized, controlled design with nine control and nine intervention sublocations, equally distributed across three districts in western Kenya. Cross-sectional household surveys were conducted before and after the delivery of the intervention. The intervention comprised provision of subsidized packs of paediatric ACT to retail outlets, training of retail outlet staff, and community awareness activities. The primary outcome was defined as the proportion of children aged 3–59 months reporting fever in the past 2 weeks who started treatment with AL on the same day or following day of fever onset. Data were collected using structured questionnaires and analyzed based on cluster-level summaries, comparing control to intervention arms, while adjusting for other covariates. Data were collected on 2,749 children in the target age group at baseline and 2,662 at follow-up. 29% of children experienced fever within 2 weeks before the interview. At follow-up, the percentage of children receiving AL on the day of fever or the following day had risen by 14.6% points in the control arm (from 5.3% [standard deviation (SD): 3.2%] to 19.9% [SD: 10.0%]) and 40.2% points in the intervention arm (from 4.7% [SD: 3.4%] to 44.9% [SD: 11.7%]). The percentage of children receiving AL was significantly greater in the intervention arm at follow-up, with a difference between the arms of 25.0% points (95% confidence interval [CI]: 14.1%, 35.9%; unadjusted p = 0.0002, adjusted p = 0.0001). No significant differences were observed between arms in the proportion of caregivers who sought treatment for their child's fever by source, or in the child's adherence to AL. CONCLUSIONS: Subsidizing ACT in the retail sector can significantly increase ACT coverage for reported fevers in rural areas. Further research is needed on the impact and cost-effectiveness of such subsidy programmes at a national scale. TRIAL REGISTRATION: Current Controlled Trials ISRCTN59275137 and Kenya Pharmacy and Poisons Board Ethical Committee for Clinical Trials PPB/ECCT/08/07. Please see later in the article for the Editors' Summary Public Library of Science 2011-05-31 /pmc/articles/PMC3104978/ /pubmed/21655317 http://dx.doi.org/10.1371/journal.pmed.1000437 Text en Kangwana et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Kangwana, Beth P. Kedenge, Sarah V. Noor, Abdisalan M. Alegana, Victor A. Nyandigisi, Andrew J. Pandit, Jayesh Fegan, Greg W. Todd, James E. Brooker, Simon Snow, Robert W. Goodman, Catherine A. The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial |
title | The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial |
title_full | The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial |
title_fullStr | The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial |
title_full_unstemmed | The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial |
title_short | The Impact of Retail-Sector Delivery of Artemether–Lumefantrine on Malaria Treatment of Children under Five in Kenya: A Cluster Randomized Controlled Trial |
title_sort | impact of retail-sector delivery of artemether–lumefantrine on malaria treatment of children under five in kenya: a cluster randomized controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104978/ https://www.ncbi.nlm.nih.gov/pubmed/21655317 http://dx.doi.org/10.1371/journal.pmed.1000437 |
work_keys_str_mv | AT kangwanabethp theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT kedengesarahv theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT noorabdisalanm theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT aleganavictora theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT nyandigisiandrewj theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT panditjayesh theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT fegangregw theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT toddjamese theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT brookersimon theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT snowrobertw theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT goodmancatherinea theimpactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT kangwanabethp impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT kedengesarahv impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT noorabdisalanm impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT aleganavictora impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT nyandigisiandrewj impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT panditjayesh impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT fegangregw impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT toddjamese impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT brookersimon impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT snowrobertw impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial AT goodmancatherinea impactofretailsectordeliveryofartemetherlumefantrineonmalariatreatmentofchildrenunderfiveinkenyaaclusterrandomizedcontrolledtrial |